Healthcare Acquisition Corp. and PharmAthene Reconfirms Receipt of Stockholder Approval for Their Merger
2007年8月4日 - 5:02AM
ビジネスワイヤ(英語)
Healthcare Acquisition Corp. (AMEX:HAQ), a publicly-traded special
purpose acquisition company, and PharmAthene, Inc., a biodefense
company developing and commercializing medical countermeasures
against biological and chemical threats, today announced that the
trading halt in the stock and warrants of the Company was the
result of inaccurate information received after its stockholders
meeting from its transfer agent. The trading was halted while the
parties and the transfer agent for the Company investigated the
accuracy of the previously reported vote. About PharmAthene, Inc.
PharmAthene was formed as a result of a merger with Healthcare
Acquisition Corp. PharmAthene is a biodefense company developing
and commercializing medical countermeasures against biological and
chemical threats. PharmAthene�s lead programs include Valortim� for
the prevention and treatment of anthrax infection and Protexia� for
the prevention and treatment of morbidity and mortality associated
with exposure to chemical nerve agents. For more information on
PharmAthene, please visit www.PharmAthene.com. Healthcare
Acquisition Corp. was a blank check company that was formed for the
specific purpose of consummating a business combination. Forward
Looking Statement Disclosure This press release contains certain
"forward-looking statements'' within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including
statements regarding the efficacy of potential products, the
timelines for bringing such products to market and the availability
of funding sources for continued development of such products.
Forward-looking statements are not historical facts but are based
on management's estimates, assumptions and projections, and are
subject to uncertainties, many of which are beyond the control of
PharmAthene. Actual results may differ materially from those
anticipated in any forward-looking statement. Factors that may
cause such differences include the risks that (a)�potential
products that appear promising to PharmAthene or any of their
collaborators cannot be shown to be efficacious or safe in
subsequent preclinical or clinical trials, (b) PharmAthene or its
collaborators will not obtain appropriate or necessary governmental
approvals to market these or other potential products,
(c)�PharmAthene may not be able to obtain anticipated funding for
its development projects or other needed funding, (d) PharmAthene
may not be able to secure funding from anticipated government
contracts and grants, and (e) PharmAthene may not be able to secure
or enforce adequate legal protection, including patent protection,
for their products. The information contained in this press release
should be read in light of such risks. The Company does not assume
any obligation to update the information contained in this press
release.
Healthcare Acquisition (AMEX:HAQ)
過去 株価チャート
から 5 2024 まで 6 2024
Healthcare Acquisition (AMEX:HAQ)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Healthcare Acquisition Corp (アメリカ証券取引所): 0 recent articles
その他のHealthcare Acquisition Corp.ニュース記事